Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKp30-directed bispecific natural killer cell engagers
- Development stage
- Preclinical
- Lead developer
- SUNHO BioPharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
NKp30-directed bispecific natural killer cell engagers (NKCEs) are a class of bispecific antibody-based immunotherapies designed to redirect and activate natural killer (NK) cells against tumor cells. These engagers simultaneously target the activating receptor NKp30 (NCR3, CD337) constitutively expressed on NK cells and a tumor-associated antigen (TAA) on cancer cells, such as CD38, GPRC5D, EGFR, or B7-H3. By bridging NK cells and tumor cells, NKp30-directed bispecific engagers promote immune synapse formation, trigger NK cell-mediated cytotoxicity, and induce the release of pro-inflammatory cytokines to eliminate malignant cells. This approach represents a promising therapeutic strategy for hematological malignancies, such as multiple myeloma and B-cell neoplasia, as well as solid tumors.
- Other names
- NKp30-directed bispecific NK cell engagerNKp-30-directed bispecific NK cell engagerNKp 30-directed bispecific NK cell engagerNKp30-directed bispecific NK cell engagersNKp-30-directed bispecific NK cell engagersNKp 30-directed bispecific NK cell engagersNKp30-directed bispecific natural killer cell engagerNKp-30-directed bispecific natural killer cell engagerNKp 30-directed bispecific natural killer cell engagerNKp30-targeted bispecific NK cell engagersNKp-30-targeted bispecific NK cell engagersNKp 30-targeted bispecific NK cell engagersNKp30-targeted bispecific natural killer cell engagersNKp-30-targeted bispecific natural killer cell engagersNKp 30-targeted bispecific natural killer cell engagers
02
Targets
B7-H3CD38 (Cluster of Differentiation 38)EGFR (Epidermal growth factor receptor)GPRC5DFCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))
Beyond the preview
Go deeper on NKp30-directed bispecific natural killer cell engagers.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKp30-directed bispecific natural killer cell engagers.